866-997-4948(US-Canada Toll Free)

Hemophilia A - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 146 Pages

Hemophilia A - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia A - Pipeline Review, H2 2017, provides an overview of the Hemophilia A (Hematological Disorders) pipeline landscape.

Hemophilia A is an X-linked, recessive disorder caused by deficiency of functional plasma clotting factor VIII (FVIII), which may be inherited or arise from spontaneous mutation. Depending on the level of FVIII activity, patients with hemophilia may present with easy bruising, inadequate clotting of traumatic injury or in the case of severe hemophilia spontaneous hemorrhage. Symptoms may include bleeding into joints, with associated pain and swelling, blood in the urine or stool, bruising, gastrointestinal tract and urinary tract hemorrhage, nosebleeds, prolonged bleeding from cuts, tooth extraction, and surgery and spontaneous bleeding.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Hemophilia A - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hemophilia A (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hemophilia A (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemophilia A and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 5, 7, 5, 19, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 3 molecules, respectively.

Hemophilia A (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hemophilia A (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Hemophilia A (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hemophilia A (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hemophilia A (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hemophilia A (Hematological Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hemophilia A (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hemophilia A (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Hemophilia A - Overview 8
Hemophilia A - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 13
Products under Development by Companies 14
Products under Development by Universities/Institutes 17
Hemophilia A - Therapeutics Assessment 18
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Hemophilia A - Companies Involved in Therapeutics Development 26
Amarna Therapeutics BV 26
Apitope International NV 26
Bayer AG 26
BioMarin Pharmaceutical Inc 27
Bioverativ Inc 27
Catalyst Biosciences Inc 28
Chugai Pharmaceutical Co Ltd 29
CSL Ltd 29
DBV Technologies SA 30
Dimension Therapeutics Inc 30
EpiVax Inc 31
Expression Therapeutics LLC 31
Green Cross Corp 31
Idogen AB 32
Immusoft Corp 32
LFB SA 33
mAbxience SA 33
Novo Nordisk AS 33
OPKO Biologics Ltd 34
Pangen Biotech Inc. 34
Pfizer Inc 34
Pharming Group NV 35
Promethera Biosciences SA 35
Sangamo Therapeutics Inc 36
Shire Plc 36
SK Chemicals Co Ltd 37
Spark Therapeutics Inc 37
UniQure NV 38
XL-protein GmbH 38
Hemophilia A - Drug Profiles 40
antihemophilic factor (recombinant) - Drug Profile 40
antihemophilic factor (recombinant) - Drug Profile 41
antihemophilic factor (recombinant) - Drug Profile 42
antihemophilic factor (recombinant) - Drug Profile 43
antihemophilic factor (recombinant) - Drug Profile 44
antihemophilic factor (recombinant) biosimilar - Drug Profile 45
antihemophilic factor (recombinant) biosimilar - Drug Profile 46
antihemophilic factor (recombinant) biosimilar - Drug Profile 47
antihemophilic factor (recombinant), PEGylated - Drug Profile 48
antihemophilic factor (recombinant), pegylated - Drug Profile 53
antihemophilic factor (recombinant), porcine sequence - Drug Profile 56
antihemophilic factor (recombinant), single chain - Drug Profile 60
ATXF-8117 - Drug Profile 64
BAY-1093884 - Drug Profile 65
BIVV-001 - Drug Profile 66
BS-027125 - Drug Profile 69
Cell Therapy to Target Coagulation Factor VIII for Hemophilia A - Drug Profile 70
concizumab - Drug Profile 71
CSL-689 - Drug Profile 73
damoctocog alfa pegol - Drug Profile 76
Deimmunized FVIII - Drug Profile 79
DTX-201 - Drug Profile 80
emicizumab - Drug Profile 82
ET-3 - Drug Profile 87
Gene Therapy for Hematological Disorders - Drug Profile 88
Gene Therapy to Activate Factor VIII for Hemophilia A - Drug Profile 89
Gene Therapy to Activate Factor VIII for Hemophilia A - Drug Profile 90
Gene Therapy to Activate Factor VIII for Hemophilia A - Drug Profile 91
HepaStem - Drug Profile 93
IN-3012 - Drug Profile 96
LR-769 - Drug Profile 98
marzeptacog alfa - Drug Profile 101
MG-1113A - Drug Profile 104
MOD-5014 - Drug Profile 105
NIBX-2101 - Drug Profile 108
PBB-8-IN - Drug Profile 109
PF-06741086 - Drug Profile 110
Recombinant Factor VIII Replacement for Hemophilia A - Drug Profile 111
Recombinant Protein to Inhibit Coagulation Factor XIV for Hemophilia A and Hemophilia B - Drug Profile 112
Recombinant Protein to Replace Coagulation Factor VIII for Hemophilia A - Drug Profile 113
Recombinant Proteins for Hemophilia A - Drug Profile 114
SB-525 - Drug Profile 115
SEL-201 - Drug Profile 117
SHP-654 - Drug Profile 118
SPK-8011 - Drug Profile 120
Stem Cell Therapy to Activate Coagulation Factor VIII for Hemophilia A - Drug Profile 122
SVF-VIIa - Drug Profile 123
valoctocogene roxaparvovec - Drug Profile 124
Hemophilia A - Dormant Projects 128
Hemophilia A - Discontinued Products 130
Hemophilia A - Product Development Milestones 131
Featured News & Press Releases 131
Appendix 142
Methodology 142
Coverage 142
Secondary Research 142
Primary Research 142
Expert Panel Validation 142
Contact Us 142
Disclaimer 143

List of Tables
Number of Products under Development for Hemophilia A, H2 2017 12
Number of Products under Development by Companies, H2 2017 14
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 15
Number of Products under Development by Universities/Institutes, H2 2017 16
Products under Development by Companies, H2 2017 17
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 18
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 19
Products under Development by Universities/Institutes, H2 2017 20
Number of Products by Stage and Target, H2 2017 22
Number of Products by Stage and Mechanism of Action, H2 2017 24
Number of Products by Stage and Route of Administration, H2 2017 26
Number of Products by Stage and Molecule Type, H2 2017 28
Hemophilia A - Pipeline by Amarna Therapeutics BV, H2 2017 29
Hemophilia A - Pipeline by Apitope International NV, H2 2017 29
Hemophilia A - Pipeline by Bayer AG, H2 2017 30
Hemophilia A - Pipeline by BioMarin Pharmaceutical Inc, H2 2017 30
Hemophilia A - Pipeline by Bioverativ Inc, H2 2017 31
Hemophilia A - Pipeline by Catalyst Biosciences Inc, H2 2017 32
Hemophilia A - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017 32
Hemophilia A - Pipeline by CSL Ltd, H2 2017 33
Hemophilia A - Pipeline by DBV Technologies SA, H2 2017 33
Hemophilia A - Pipeline by Dimension Therapeutics Inc, H2 2017 34
Hemophilia A - Pipeline by EpiVax Inc, H2 2017 34
Hemophilia A - Pipeline by Expression Therapeutics LLC, H2 2017 34
Hemophilia A - Pipeline by Green Cross Corp, H2 2017 35
Hemophilia A - Pipeline by Idogen AB, H2 2017 35
Hemophilia A - Pipeline by Immusoft Corp, H2 2017 35
Hemophilia A - Pipeline by LFB SA, H2 2017 36
Hemophilia A - Pipeline by mAbxience SA, H2 2017 36
Hemophilia A - Pipeline by Novo Nordisk AS, H2 2017 37
Hemophilia A - Pipeline by OPKO Biologics Ltd, H2 2017 37
Hemophilia A - Pipeline by Pangen Biotech Inc., H2 2017 37
Hemophilia A - Pipeline by Pfizer Inc, H2 2017 38
Hemophilia A - Pipeline by Pharming Group NV, H2 2017 38
Hemophilia A - Pipeline by Promethera Biosciences SA, H2 2017 39
Hemophilia A - Pipeline by Sangamo Therapeutics Inc, H2 2017 39
Hemophilia A - Pipeline by Shire Plc, H2 2017 40
Hemophilia A - Pipeline by SK Chemicals Co Ltd, H2 2017 40
Hemophilia A - Pipeline by Spark Therapeutics Inc, H2 2017 41
Hemophilia A - Pipeline by UniQure NV, H2 2017 41
Hemophilia A - Pipeline by XL-protein GmbH, H2 2017 42
Hemophilia A - Dormant Projects, H2 2017 131
Hemophilia A - Dormant Projects, H2 2017 (Contd..1), H2 2017 132
Hemophilia A - Discontinued Products, H2 2017 133

List of Figures
Number of Products under Development for Hemophilia A, H2 2017 12
Number of Products under Development by Companies, H2 2017 13
Number of Products under Development by Universities/Institutes, H2 2017 16
Number of Products by Targets, H2 2017 21
Number of Products by Stage and Targets, H2 2017 21
Number of Products by Mechanism of Actions, H2 2017 23
Number of Products by Stage and Mechanism of Actions, H2 2017 23
Number of Products by Routes of Administration, H2 2017 25
Number of Products by Stage and Routes of Administration, H2 2017 25
Number of Products by Top 10 Molecule Types, H2 2017 27
Number of Products by Stage and Top 10 Molecule Types, H2 2017 27

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *